Ditchcarbon
  • Customers
  1. Organizations
  2. Viatris
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a day ago

Viatris

Company website

Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn, is headquartered in the United States. Established in 2020, Viatris operates in over 165 countries, focusing on the pharmaceutical industry with a commitment to providing access to high-quality medicines. The company’s core business areas include generic and specialty pharmaceuticals, biosimilars, and over-the-counter products. Viatris is renowned for its extensive portfolio, which features a diverse range of medications that address various health conditions, including chronic diseases and infectious diseases. Its unique approach combines a broad product offering with a strong emphasis on patient access and affordability. With a significant market presence, Viatris has achieved notable milestones, including the successful integration of its legacy companies and a commitment to sustainable healthcare solutions.

DitchCarbon Score

How does Viatris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

49

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Viatris's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.

71%

Let us know if this data was useful to you

Viatris's reported carbon emissions

In 2024, Viatris reported total carbon emissions of approximately 355,000,000 kg CO2e, with Scope 1 emissions at about 95,000,000 kg CO2e and Scope 2 emissions at approximately 260,000,000 kg CO2e. This marks a slight decrease from 2022, when total emissions were about 370,000,000 kg CO2e. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 42% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2020 baseline. Additionally, Viatris aims to cut its absolute Scope 3 emissions by 25% within the same timeframe, which includes emissions from purchased goods and services, capital goods, and upstream transportation. In the UK, Viatris reported Scope 2 emissions of approximately 295,000 kg CO2e in 2023, alongside Scope 3 emissions of about 4,105,000 kg CO2e. The company has also committed to achieving net zero emissions by 2050 for its UK operations. Viatris's targets are aligned with the Science Based Targets initiative (SBTi), ensuring that their reduction goals are consistent with the global aim to limit warming to 1.5°C. Overall, Viatris is actively working towards significant emissions reductions while maintaining transparency in its sustainability efforts.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
302,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 2
354,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Viatris's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Viatris is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Viatris is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 7 hours ago

Bayer Pharma AG

DE
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Sai Life Sciences

IN
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 6 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Haleon plc

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250829.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy